Stuart Therapeutics Announces Corneal Epithelial Healing and Organization Pre-Clinical Results for its Potential Dry Eye Therapeutic
October 4th, 2018, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol). The company announced additional important results from its mouse eye wound tests. Previous results showed statistically significant results
Stuart Therapeutics Announces Important Pre-Clinical Results for ST-100
September 17th, 2018, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol). Mouse eye wound tests conducted at the University of Louisville demonstrated rapid, high quality healing of corneal wounds,
Stuart Therapeutics has been selected as a semi-finalist in the BioPitch competition at the 21st annual BioFlorida Conference
September 12th, 2018, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has been selected as a semi-finalist in the BioPitch competition at the 21st annual BioFlorida Conference, October 14th – 16th in Ft. Lauderdale, Florida. The BioPitch competition annually selects 15 companies